Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart-liver co-management - PubMed
6 days ago
- #pharmacotherapy
- #cardiovascular disease
- #MASLD
- Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about 30% of adults, with 30% progressing to metabolic dysfunction-associated steatohepatitis (MASH).
- Cardiovascular disease is the leading cause of death in MASH patients, necessitating integrated heart-liver co-management.
- MASLD and cardiovascular disease share common mechanisms like insulin resistance, inflammation, dyslipidaemia, and oxidative stress.
- Effective MASLD management requires addressing hepatic and cardiovascular risks, but faces challenges like underdiagnosis and lack of collaboration between specialists.
- Three pharmacological approaches are discussed: metabolic-targeted therapies, liver-targeted therapies, and cardiovascular therapies, each with benefits and limitations.